suPAR predicts type 1 diabetes complications
Sat Jun 29 2019
“Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes” published in Diabetes Care.
In this study, Curovic et al investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes.
667 patients with type 1 diabetes with various degrees of albuminuria were included. The end points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality.
The follow-up was 5.2–6.2 years.
The authors concluded that in patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality.
In addition to that, suPAR contributes significantly to discrimination for the end points.
